BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21143326)

  • 1. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis.
    Molle V; Gulten G; Vilchèze C; Veyron-Churlet R; Zanella-Cléon I; Sacchettini JC; Jacobs WR; Kremer L
    Mol Microbiol; 2010 Dec; 78(6):1591-605. PubMed ID: 21143326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Dias MV; Vasconcelos IB; Prado AM; Fadel V; Basso LA; de Azevedo WF; Santos DS
    J Struct Biol; 2007 Sep; 159(3):369-80. PubMed ID: 17588773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.
    Oliveira JS; Pereira JH; Canduri F; Rodrigues NC; de Souza ON; de Azevedo WF; Basso LA; Santos DS
    J Mol Biol; 2006 Jun; 359(3):646-66. PubMed ID: 16647717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid.
    Vilchèze C; Wang F; Arai M; Hazbón MH; Colangeli R; Kremer L; Weisbrod TR; Alland D; Sacchettini JC; Jacobs WR
    Nat Med; 2006 Sep; 12(9):1027-9. PubMed ID: 16906155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function of heterologous Mycobacterium tuberculosis InhA, a type 2 fatty acid synthase enzyme involved in extending C20 fatty acids to C60-to-C90 mycolic acids, during de novo lipoic acid synthesis in Saccharomyces cerevisiae.
    Gurvitz A; Hiltunen JK; Kastaniotis AJ
    Appl Environ Microbiol; 2008 Aug; 74(16):5078-85. PubMed ID: 18552191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the enoyl-ACP reductase of Mycobacterium tuberculosis (InhA) in the apo-form and in complex with the active metabolite of isoniazid pre-formed by a biomimetic approach.
    Chollet A; Mourey L; Lherbet C; Delbot A; Julien S; Baltas M; Bernadou J; Pratviel G; Maveyraud L; Bernardes-Génisson V
    J Struct Biol; 2015 Jun; 190(3):328-37. PubMed ID: 25891098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis.
    Veyron-Churlet R; Zanella-Cléon I; Cohen-Gonsaud M; Molle V; Kremer L
    J Biol Chem; 2010 Apr; 285(17):12714-25. PubMed ID: 20178986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of enoyl-acyl carrier protein reductase InhA impacts mycobacterial growth and survival.
    Khan S; Nagarajan SN; Parikh A; Samantaray S; Singh A; Kumar D; Roy RP; Bhatt A; Nandicoori VK
    J Biol Chem; 2010 Nov; 285(48):37860-71. PubMed ID: 20864541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
    Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
    Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis.
    Rozwarski DA; Grant GA; Barton DH; Jacobs WR; Sacchettini JC
    Science; 1998 Jan; 279(5347):98-102. PubMed ID: 9417034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
    Oliveira JS; de Sousa EH; de Souza ON; Moreira IS; Santos DS; Basso LA
    Curr Pharm Des; 2006; 12(19):2409-24. PubMed ID: 16842188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
    Tripathi A; Wadia N; Bindal D; Jana T
    Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biosynthesis and regulation of mycolic acids in Mycobacterium tuberculosis--a review].
    Luo H; Pang L; Xie J
    Wei Sheng Wu Xue Bao; 2012 Feb; 52(2):146-51. PubMed ID: 22586991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases from Mycobacterium tuberculosis type II fatty acid synthase system.
    Slama N; Leiba J; Eynard N; Daffé M; Kremer L; Quémard A; Molle V
    Biochem Biophys Res Commun; 2011 Sep; 412(3):401-6. PubMed ID: 21819969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach.
    Stigliani JL; Arnaud P; Delaine T; Bernardes-Génisson V; Meunier B; Bernadou J
    J Mol Graph Model; 2008 Nov; 27(4):536-45. PubMed ID: 18955002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.
    Banerjee A; Dubnau E; Quemard A; Balasubramanian V; Um KS; Wilson T; Collins D; de Lisle G; Jacobs WR
    Science; 1994 Jan; 263(5144):227-30. PubMed ID: 8284673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An inorganic iron complex that inhibits wild-type and an isoniazid-resistant mutant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis.
    Oliveira JS; Sousa EH; Basso LA; Palaci M; Dietze R; Santos DS; Moreira IS
    Chem Commun (Camb); 2004 Feb; (3):312-3. PubMed ID: 14740053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis.
    Vilchèze C; Morbidoni HR; Weisbrod TR; Iwamoto H; Kuo M; Sacchettini JC; Jacobs WR
    J Bacteriol; 2000 Jul; 182(14):4059-67. PubMed ID: 10869086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.